Friday, 16 Nov 2018

You are here

Low Short-Term Risks of NSAIDs in High Risk Patients

JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-37 days of exposure). 

A study of 2,415,291 musculoskeletal-related primary care visits and 814,049 older adults (mean age 75.3 years) who also had hypertension, heart failure, or CKD, found that nearly 10% were prescribed NSAID therapy.

A match cohort analysis (35 552 matched pairs of NSAID exposed and nonexposed) showed similar rates of cardiac complications (0.8% vs 0.8%), renal complications (0.1% vs 0.1%), and death (0.1% vs 0.1%).

Thus, even though NSAIDs were frequently used in high-risk patients, NSAID exposure was not associated with increased risk of short-term, safety-related outcomes.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Unfortunately, this data can be misinterpreted. In clinical practice painful conditions are not usually acute and short-term (exceptly secondary to overuse/ trauma). Instead it is not uncommon to be chronic and recurrent. Therefore, although short-term NSAIDs use appears to be safe in CKD, heart failure, and hypertension patients, its recurrent use can not be considered safe. I believe that, just like opioid abuse, anti-inflammatory abuse should be tackled and even if it proves to be safe in some situations, its use should be discouraged through constant patient education, reinforcing them to not “autoprescribe” NSAIDs.

More Like This

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs. 

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.

Anti-phospholipid Antibodies and Myocardial Infarction.

The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal Medicine reports.

Update on Immune Checkpoint Inhibitor Toxicity

JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.

New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis

The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.

It addresses safety recommendations for all biologic therapies approved by the National Institute for Health and Care Excellence (NICE) up to June 2016, for use in all inflammatory arthritides [RA, PsA and axial SpA (SpA) including AS].